Job Trends
Labor Market Reports
BioSpace’s Q3 2025 U.S. Life Sciences Job Market Report reveals a turbulent quarter for biopharma hiring, with record declines in job postings, rising layoffs, and cautious employer sentiment shaping the industry’s employment landscape.
BioSpace data show biopharma professionals faced increased competition for fewer employment opportunities during the second quarter of 2025, with increased pressure from further layoffs.
Establishing trust through thought leadership is no longer optional in today’s cautious biopharma market. Learn how strategic insights and targeted outreach can turn awareness into high-converting leads.
Now Hiring
Looking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you.
Looking for a biopharma job in New York? Check out the BioSpace list of eight companies hiring life sciences professionals like you.
Of the 25 companies receiving tax incentives in Massachusetts, 23 will add jobs outside of Boston and Cambridge. Medtronic, which is receiving the largest award, will create 220 roles in Billerica. Other recipients include AbbVie, Dyne Therapeutics and Viridian Therapeutics.
Career Advice
Clarity on employment terms is essential to protect careers. In this column, Kaye/Bassman’s Michael Pietrack speaks to employment attorney Howard Matalon, JD, partner at OlenderFeldman, on how to evaluate the fine print of an employment agreement.
THE LATEST
The primary endpoint was change from baseline to 76 weeks in the Integrated Alzheimer’s Disease Rating Scale (iADRS).
The deal adds Kymab’s lead asset KY1005 to its pipeline, a human monoclonal antibody targeting key immune system regulator OX40L.
ArsenalBio has entered into a multi-year discovery partnership with Bristol Myers Squibb to develop next-generation T cell therapies for solid tumors.
Pfizer is giving itself a corporate facelift, dropping its traditional blue-pill company logo in favor of a double helix DNA spiral that reflects the advances in medical science that have placed the curing of multiple diseases within reach.
With the new year comes a changing of the guard at Pfizer. After two years of helming the company’s pharma operations, Chief Medical Officer Mace Rothenberg announced his departure from Pfizer on social media.
The new state-of-the-art facility, dubbed the “Factory of the Future,” will span 110,000 square feet and will be located in the city of Wilsonville, Oregon.
Yesterday it was reported that the two companies were working to make more of their vaccine than the 1.3 billion it promised to manufacture in 2021.
An investigational asthma treatment, tezepelumab, under development by Amgen and AstraZeneca failed to reduce asthma patients’ dependence on corticosteroids.
Surface Oncology has agreed to grant exclusive worldwide licensing rights to GlaxoSmithKline for the development and commercialization of Surface Oncology’s SRF813, a fully human IgG1 antibody and immunotherapy designed to treat cancer.
Despite some setbacks, the company anticipates its vaccine could be available for use in the United Kingdom within the next several weeks.